Biogaia Ab

Other

Biogala Ab

Biogaia Biologics Ab

Biogaia Biologies Ab

Bo Mollstam

Eamonn Connolly

Ivan A Casas

Fredrik Magnusson

Filip Sauer

Elisabeth Sjoberg

James Versalovic

Bengt Bjorksten

Karin Oberg

Bhanu Priya Ganesh

Leif Einar Stern

Stefan Roos

Hans Jonsson

Ivan Casas

Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.

Selection of bacterial strains useful in allergy treatment

The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.

Use of selected lactic acid bacteria for reducing infantile colic

New strains ofthat have been selected for their capability of improved reduction the number ofin the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries

This invention relates to the selection and use of nonpathogenic, lysine-uptake stimulating lactic acid bacteria strains, and products and methods using such strains for example for improvement of fur-coat and claws quality in pet-animals.

Use of lactic acid bacteria for improving food lysine absorption of pet animals

Selected strains ofand products containing cells of the selected strains to improve breast milk for feeding to babies, more precisely to increase the levels of the anti-inflammatory cytokine IL10 in the milk and reduce the risk that the feeding baby will develop allergies and simultaneously reduce the cause and thereby the amount of TGF-beta-2 in the milk, thus resulting in reduced risk for the lactating mother to develop mastitis.

Stabilized bacterial formulation

Strains ofwhich have been selected for their capability of reducing gastrointestinal inflammation, such as that due to, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated withfor administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

[object Object]

Method for improved breast milk feeding to reduce the risk of allergy

Growing community of inventors

Lerum, Sweden

Bo Mollstam